Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for psoriasis in early trial

NCT ID NCT06602219

Disease control Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study tested an experimental oral drug called LY4100511 (DC-853) in 222 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive different doses of the drug or a placebo. The main goal was to see how well the drug clears skin and whether it is safe. The trial has been completed, and results are being analyzed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY4100511 (DC-853)
What this could lead to
If successful, this could lead to a new oral treatment option for moderate-to-severe plaque psoriasis, helping clear skin and reduce symptoms.
What could go wrong
This is a Phase 2 trial with only 222 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

222 people

The number who actually took part.

Started

Oct 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization * Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive). * Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention. * Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study Exclusion Criteria: * Have had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator. * Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis. * Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus. * Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics). * Have a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku

    Gdansk, Pomeranian Voivodeship, 80-382, Poland

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni

    Gdynia, Pomeranian Voivodeship, 81-537, Poland

  • AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu

    Wroclaw, Lower Silesian Voivodeship, 50-381, Poland

  • Allergo-Derm Bakos Kft

    Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary

  • Cahaba Dermatology Skin Health Center

    Birmingham, Alabama, 35244, United States

  • Center for Clinical Studies, LTD.LLP

    Webster, Texas, 77598, United States

  • Center for Dermatology Clinical Research

    Fremont, California, 94538-1614, United States

  • Centrum Medyczne Angelius Provita

    Katowice, 40-611, Poland

  • Centrum Medyczne Reuma Park NZOZ

    Warsaw, 02-665, Poland

  • Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska

    Wroclaw, Lower Silesian Voivodeship, 50-566, Poland

  • Clinical Best Solutions

    Warsaw, Masovian Voivodeship, 00-710, Poland

  • Clinical Science Institute

    Santa Monica, California, 90404, United States

  • Clintrial s.r.o.

    Prague, Praha 10, 10100, Czechia

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • DermEdge Research

    Mississauga, Ontario, L4Y 4C5, Canada

  • DermEffects - Probity - PPDS

    London, Ontario, N6H 5L5, Canada

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dermatology Trial Associates

    Bryant, Arkansas, 72022, United States

  • Dermatrials Research Inc.

    Hamilton, Ontario, L8N 1Y2, Canada

  • Dermoklinika Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Direct Helpers Research Center

    Hialeah, Florida, 33012, United States

  • Driven Research

    Coral Gables, Florida, 33134, United States

  • Endeavor Clinical Trials Center - Dermatology - Skokie

    Skokie, Illinois, 60077-1049, United States

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, 100 34, Czechia

  • First OC Dermatology Research Inc

    Fountain Valley, California, 92708, United States

  • ForCare Clinical Research

    Tampa, Florida, 33613, United States

  • GCP Global Clinical Professionals, LLC

    St. Petersburg, Florida, 33713-8012, United States

  • Gyongyosi Bugat Pal Korhaz

    Gyöngyös, 3200, Hungary

  • Igarashi Dermatological Clinic

    Tokyo, Japan

  • Interior Dermatology Centre - Probity - PPDS

    Kelowna, British Columbia, V1W 4V5, Canada

  • Katahira Dermatology Urology Clinic

    Kagoshima, Kagoshima-ken, 890-0063, Japan

  • Kozni ambulance Fialova, s.r.o. - CRC - PPDS

    Prague, 160 00, Czechia

  • Kume Clinic

    Sakai-shi, Osaka, 593-8324, Japan

  • Laser Clinic Dermatologia Laserowa Medycyna Estetyczna

    Szczecin, West Pomeranian Voivodeship, 70-332, Poland

  • Lawrence J Green, M.D, LLC

    Rockville, Maryland, 20850, United States

  • Lovegrove Dermatology - Probity - PPDS

    London, Ontario, N6A 5R9, Canada

  • Lynderm Research Inc.

    Markham, Ontario, L3P 1X2, Canada

  • MedMare Bt

    Veszprém, 8200, Hungary

  • Medical Corporation Kojinkai Sapporo Skin Clinic

    Sapporo, Hakkaido, 060-0063, Japan

  • MensingDerma Research GmbH

    Hamburg, 22391, Germany

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, 450-0003, Japan

  • Ohyama Dermatology Clinic

    Kumamoto, Kumamoto, 861-4101, Japan

  • Pratia Pardubice a.s. - PRATIA - PPDS

    Pardubice, 530 02, Czechia

  • Pratia Prague s.r.o. - PRATIA - PPDS

    Prague, 13000, Czechia

  • Praxis Dr. med. Virgil-Oreste Mihaescu Facharzt fr Dermatologie und STD

    Augsburg, Bavaria, 86150, Germany

  • Renstar Medical Research

    Ocala, Florida, 34470, United States

  • Shirasaki dermatology clinic

    Takaoka, Toyama, 933-0871, Japan

  • Simcoderm Medical & Surgical Dermatology Centre

    Barrie, Ontario, L4M 7G1, Canada

  • Skin Care West

    Nanaimo, British Columbia, V9T1W1, Canada

  • Synexus Polska Sp. z o.o. Oddzial w Czestochowie

    Częstochowa, Silesian Voivodeship, 42-202, Poland

  • Tachikawa Dermatology Clinic

    Tachikawa, Tokyo, 190-0023, Japan

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, 160-0023, Japan

  • Universitätsklinikum Carl Gustav Carus an der TU

    Dresden, 1307, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Hesse, 60590, Germany

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie

    Rzeszów, Podkarpackie Voivodeship, 35-055, Poland

  • Zenith Research, Inc.

    Beverly Hills, California, 90212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.